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1. Introduction 
Recent basic research has aroused great interest in the therapeutic potential of 
phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, vardenafil and taladafil, 
for the treatment of cystic fibrosis (CF). CF is the most common, life-threatening, 
recessively inherited disease in Caucasian populations. An estimated 1 in 2,500 
Caucasian live births are affected and approximately 80,000 people in the world are 
diagnosed with CF. Due to mutation in the CF transmembrane conductance regulator 
(CFTR) gene [1,2], which encodes the main chloride channel expressed in epithelia, CF 
causes abnormal mucociliary clearance mainly in the lungs, leading to a vicious cycle of 
obstruction/infection/inflammation that progressively and irreversibly damages the 
lung tissue and architecture. Although many organs are affected in CF, pulmonary 
disease is the major cause of morbidity and mortality [3,4]. Despite more than two 
decades of intensive investigation of the genetics [1,2], pathophysiology and clinical 
phenotypes of CF [3,4], there is still no cure for CF. As a matter of fact, therapies have 
been limited to alleviating clinical manifestations. Although life expectancy and quality 
of life have progressively improved, CF continues to inflict major burdens and to shorten 
lives.  
The most common disease allele, p.Phe508del (F508del), corresponding to deletion of a 
single phenylalanine residue at position 508 of a single polypeptide chain of 1480 amino 
acids, interferes with CFTR function because the mutant protein does not efficiently fold 
into the native protein structure. Although the mutant F508del is correctly translated, it is 
held back in the endoplasmic reticulum; the misfolded protein is directed towards 
proteosomal degradation and fails to reach the apical membrane of many epithelial cells [5]. 
An effective candidate drug to treat F508del-CF patients should be able to correct the 
localization of CFTR protein by increasing its expression at the apical membrane of 
epithelial cells. Indeed, it has been recognized that rescuing F508del-CFTR to the plasma 
membrane is followed by an improved efflux of chloride ions across the epithelium related 
to some residual channel activity of the mutant protein [6]. Therefore, finding a compound 
that promotes CFTR channel activity would be of great benefit. Searching for such 
compounds, we and others have demonstrated the potential of PDE5 inhibitors for the 
treatment of CF. Indeed, basic studies have provided evidence that PDE5 inhibitors, already 
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in clinical use for the treatment of erectile dysfunction and/or of pulmonary arterial 
hypertension, rescue F508del-CFTR trafficking [7,8] and improve its channel activity [9,10].  
PDE are enzymes that regulate the intracellular levels of the second messengers, such as 
cyclic AMP and GMP, by controlling their rate of degradation. The enzymes catalyze the 
hydrolysis of the 3’ cyclic phosphate bonds of adenosine (Figure 1) and/or guanosine 3’5’ 
cyclic monophosphate.  
 
Fig. 1. Structure of cyclic AMP. Arrow indicates the site of hydrolyses by 
phosphodiesterases: the 3’ cyclic phosphate bond.  
Many of the early studies on cyclic nucleotides were directed toward understanding PDE 
activity since at that time it was much easier to measure PDE activity than either cAMP or 
cGMP themselves or the enzymes that catalyzed their synthesis. More recently, it became 
clear that there were likely to be multiple isoforms of PDEs with different kinetic and 
regulatory properties. They are characterized by their specificity and sensitivity to calcium-
calmodulin and by their affinity for cAMP or cGMP [11]. PDEs were classified on the basis 
of their amino acid sequences, substrate specificities, pharmacological properties and tissue 
distributions. 
2. Cyclic nucleotide phosphodiesterases 
2.1 Isoforms of phosphodiesterases 
It is now very clear that any single cell type can express several different PDE isoforms and 
also that the nature and localization of these PDEs are likely to be major regulators of the 
local concentrations of cAMP or cGMP in the cell. Eleven cyclic PDE families with varying 
selectivities for cAMP and/or cGMP have been identified in mammalian tissues [12-16] 
(Table 1). 
PDEs are therefore important regulators of diverse biochemical mechanisms mediated by 
cAMP and /or cGMP. Despite this heterogeneity, there is a surprising degree of homology 
within their catalytic domains; however, slight structural differences in these domains 
determine whether a PDE is cAMP-specific (PDE4, PDE7, PDE8), cGMPspecific (PDE5, 
PDE6, PDE9) or has dual substrate specificity (PDE1, PDE2, PDE3, PDE10, PDE11) [17-18]. 
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PDE 
isoenzyme 
Substrate 
Km 
(µM) 
cAMP 
Km 
(µM) 
GMP 
Tissue expression 
Specific 
inhibitors 
1 
Ca2+/calmodulin 
stimulated 
80 3 
Heart, brain, lung, smooth 
muscle, T lymphocytes, sperm 
KS505a, bepril, 
Vinpocetine, 
Flunarizine and 
Amiodarone 
2 
cGMP- 
stimulated 
30 10 
Adrenal gland, heart, lung, 
liver, platelets 
EHNA, BAY 60-
7550, Oxindole 
and PDP 
3 
cGMP-inhibited 
cAMP-selective 
0.4 0.3 
Heart, lung, liver, platelets, 
Kidney, T lymphocytes, 
adipocytes, inflammatory cells 
Cilostamide, 
Enoxamone, 
Milrinone, 
Siguazodan 
4 cAMP-specific 4  
Sertoli cells, kidney, brain, liver, 
lung, inflammatory cells 
Rolipram, 
Roflumilast, 
Cilomilast, 
Drotaverine, 
ibudilast 
5 cGMP-specific 150 1 
Lung, platelets, vascular, 
smooth muscle 
Sildenafil, 
Vardenafil, 
Tadalafil, 
Zaprinast 
6 cGMP-specific  60 Photoreceptor Dipyridamole 
7 
cAMP-specific, 
high-affinity 
700 15 
Skeletal muscle, heart, kidney, 
Brain, pancreas, T lymphocytes 
BRL-50481, 
BC30 
8 cAMP-selective 0.06  
Testes, eye, liver, skeletal muscle,
Heart, kidney, ovary, brain, 
T lymphocytes 
PF-04957325 
9 cGMP-specific 230 0.2 Kidney, liver, lung, brain BAY 73-6691 
10 
cGMP-sensitive, 
cAMP-selective 
0.2 13 Testes, brain None 
11 
cGMP-sensitive, 
dual specificity 
0.7 0.6 
Skeletal muscle, prostate, kidney,
liver, pituitary, testes and 
salivary glands 
None 
Table 1. Phosphodiesterase families and specific inhibitors 
PDE1s are calcium dependent activators or regulators: they have been shown to activate 
cyclic nucleotide PDE in a calcium-dependent manner. PDE1s are present in many tissues 
and are abundant mainly in the central nervous system, heart, skeletal muscle and kidney 
[19-21]. 
PDE2 metabolizes both cGMP and cAMP although its affinity for cGMP is slightly higher 
than for cAMP [22]. High PDE2 activity can be found in heart [23] and brain. Lower 
expression of PDE2 was found in lung, placenta, liver, skeletal muscle, kidney and pancreas 
[24]. 
PDE3s are characterized by their high affinity and their ability to metabolize both cAMP and 
cGMP. They are also distinguished by their ability to be activated by several 
phosphorylation pathways including the PKA and PI3K/PKB pathways. PDE3s are 
moderately expressed in platelets as well as in vascular smooth muscle [25] and oocytes. 
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PDE4s have a higher affinity for cAMP, they are expressed in inflammatory cells such as T 
cells, B cells, eosinophils, neutrophils, airway epithelial cells and endothelial cells [26-28], 
cardiovascular tissues and smooth muscles. Differential expression of PDE4s can be 
modulated by inflammatory factors and expressed in lung macrophages from patients with 
chronic obstructive pulmonary disease (COPD).  
PDE5 has a higher affinity for cGMP and was identified, isolated and characterized in rat 
platelets [29,30] and rat lung [31,32]. PDE5 is widely expressed in pulmonary vascular 
smooth muscle of pulmonary arteries and veins, bronchial blood vessels and airway smooth 
muscle [33]. Recent data show that PDE5 may modulate pulmonary arterial pressure 
induced by cardiac hypertrophy and fibrosis ([34]. 
PDE6s are phosphodiesterases characterized by their affinity for cGMP and are expressed in 
the photoreceptor outer segments of the mammalian retina, in which they mediate 
transduction of the light signal into an electrical response [35].  
PDE7 are characterized by their high affinity and selectivity for cAMP as substrate. PDE7 
protein expression is largest in T cell lines, blood T cells, epithelial cell lines, airway and 
vascular smooth muscle cells, lung fibroblasts and eosinophils and in neutrophils [36]. 
PDE8s are cAMP specific and have a very high affinity for cAMP as a substrate. PDE8s are 
distributed in various human tissues and are abundant in testis [37-40]. Functionally, PDE8s 
have been reported to be involved in regulation of T-cell activation [41], chemotaxis of 
activated lymphocytes [42], modulation of testosterone production in Leydig cells [43], and 
possibly potentiation of biphasic insulin response to glucose [44]. 
PDE9 is one of the more recently discovered PDE families. It is perhaps most notable as 
the PDE family having the highest affinity for cGMP. Further, compared with other 
cGMP-specific PDEs, PDE9 apparently lacks the non catalytic cGMP-binding domain, 
which is present in PDE5, PDE6, and also PDE2. The mRNA encoding PDE9 is well 
expressed in many examined human tissues, including spleen, small intestine, and brain 
[45,46]. 
PDE10 was isolated and characterized as a dual-substrate gene family in 1999 from mouse 
[47] as well as from human fetal lung [48] and fetal brain [49]. This PDE family was recently 
shown to be associated to the progressive neurodegenerative Huntington’s disease (HD) 
since PDE10 mRNA decreases prior to the onset of motor symptoms in transgenic HD mice 
expressing exon 1 of the human Huntington gene [50]. 
PDE11 are characterized by their high affinity for both cAMP and cGMP, although kinetic 
characteristics for the variants are different [51-53]. PDE 11 mRNA occurs at higher levels in 
skeletal muscle, prostate, kidney, liver, pituitary and salivary glands, and testis. 
3. PDE inhibitors as pharmacological tools in the treatment of diseases 
The principle that inhibition of PDE activity could be a valid therapeutic tool is now well 
accepted. It is commonly accepted that concentrations of cAMP and cGMP in most cells are 
typically <1 to 10µM [54]. This means that a competitive inhibitor would not need to 
compete with very high levels of endogenous substrate in order to be effective.  
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The history of the PDE starts with the work of Henry Hyde Salter in 1887. It has been shown 
that caffeine has a bronchodilatator effect and that it was a non selective inhibitor of PDE 
activity. The caffeine and other xanthines have been used as therapeutic agents in 
respiratory diseases [55]. 
Inhibition of cyclic nucleotide PDEs allow cAMP/cGMP concentrations to increase within 
cells. Therefore, inhibition of PDE is a useful way of causing a variety of cellular effects and 
can influence various physiological mechanisms. Many PDE inhibitors are recognized as 
pharmacological agents. In fact, some compounds such as theophylline have been used as 
drugs in medical practice long before they were identified as PDE inhibitors. Currently, both 
non selective and selective PDE inhibitors are explored as therapeutic agents. 
3.1 Non selective PDE inhibitors 
Non selective inhibitors of the PDE such as theophylline, caffeine and papaverin have 
been used for more than 70 years in the western world for treatment of various diseases 
[56-59] and were identified as PDE inhibitors, i.e. as compounds that specifically inhibit 
the activity of PDE and not of other phosphohydrolases. During the last 10 years, a better 
understanding of physiological roles, cellular expression, specific inhibitors of the PDE 
isoforms, as well as of their clinical indications has been acquired. These non selective 
PDE inhibitors inhibit PDE competitively with low affinity and do not discriminate 
between PDE isozymes; both cAMP and cGMP–PDE activities are inhibited. Theophylline 
and other methylxantines are potent antagonists of adenosine receptors [60]. Theophylline 
had been prescribed for the first time in 1937 for the treatment of asthma; it is also 
perceived to be an orally active anti-inflammatory agent for use in asthma or COPD 
[57,61]. Paraxanthine, the primary metabolite of caffeine, acts through the ryanodine 
receptor to elevate intracellular calcium concentration and increases viability of neuronal 
cells in culture [62]. 3-isobutyl-1-methylxanthine (IBMX) was synthesized by Wells et al 
(1975), it has a much higher affinity for PDEs and at low concentrations, it preferentially 
inhibits cGMP-PDE over cAMP-PDE [63].  
3.2 Selective PDE inhibitors 
3.2.1 Inhibitors without therapeutic action 
PDE2 is involved in a variety of physiological processes. The availability of PDE selective 
inhibitors has greatly facilitated the elucidation of PDE2 function in various tissues. One of 
the first specific inhibitors for PDE2 was erythro 9-(2 hydroxy-3-nonyl) adenine (EHNA) 
which potentiates the effects of NMDA (N-methyl-D-aspartate) activated receptors in 
cGMP, but has no effect on cAMP concentration [64]. EHNA is also a potent inhibitor of 
adenosine deaminase (ADA); it exerts a concentration dependent inhibition of the cGMP-
stimulated PDE2 but does not inhibit other PDEs [65]. The strong expression of PDE2 in 
neurons of the hippocampus and cortex [66] suggests that this enzyme may control 
intraneuronal second messenger concentrations in these areas. Bayer (Germany) has 
developed a selective PDE2 inhibitor, the Bay 60-7550, which enhances long-term 
potentiation of synaptic transmission without altering basal synaptic transmission. BAY 60-
7550 can improve memory functions by enhancing neural plasticity [67,68]. 
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3.2.2 Inhibitors with therapeutic action 
Some selective PDE inhibitors act directly on the catalytic site of PDE1s, such as vinpocetine. 
This PDE inhibitor has been used in memory loss [69] and in treating detrusor instabilities 
and urgency incontinence [70]. PDE inhibitor can improve neural plasticity or restore this 
function in different neurological conditions [71,72]. Vinpocetine treatment was also shown 
to revert the effects of early alcohol exposure in learning performance in the water maze 
[73]. It was recently demonstrated that vinpocetine has a strong anti-inflammatory effect 
[74]. This new action of vinpocetine, combined with its potential to enhance neuronal 
plasticity suggest that this drug may have beneficial effects in conditions such as Alzheimer 
and Parkinson diseases where inflammation and poor neuronal plasticity are present [75]. 
There are a relatively large number of PDE3 selective inhibitors including milrinone, 
cilostamide and cilostazol, which were identified as potential therapeutic tools in 
cardiovascular disease and asthma. Inhibition of PDE3 activity increase L-type Ca2+ currents 
in cardiomyocytes isolated from human, rat and frog heart, an effect that contributes to the 
positive inotropic effects of these inhibitors [76]. Milrinone has an inotropic and vasodilator 
effect for “wet and cold” heart failure [77], a case of heart failure with congestion and 
hypoperfusion [78]. It has been reported that the combination of inhaled and intravenous 
milrinone could be an effective treatment of secondary pulmonary hypertension in high-risk 
cardiac valve surgery patients [79]. 
PDE4 inhibitors have been developed for the treatment of asthma and COPD, diseases 
characterised by inflammatory and immune responses [80].  Rolipram is a highly selective 
first generation PDE4 inhibitor that has been used for many years as a research tool to 
investigate the role of PDE4. Several studies have shown that rolipram inhibits neutrophilic 
and eosinophilic inflammation [81]; it proved to be an effective antidepressant, but  side 
effects such as nausea and gastro-intestinal disturbance terminated its clinical development 
[82]. Roflumilast was beneficial, as assessed by improvement in lung function, even when 
added to a long acting ǃ2 agonist or a long acting inhaled antimuscarinic [83]. 
The use of inhibitors of PDE5 (sildenafil (Viagra; Pfizer Inc, US), vardenafil (Levitra; 
GlaxoSmithKline, UK) and tadalafil (Cialis; Eli Lilly, US)) in the treatment of male erectile 
dysfunction is the first commercial success for PDE inhibitors. Sildenafil (under the tradename 
Revatio) and tadalafil (under the tradename Adcirca) have also been approved for the treatment 
of pulmonary arterial hypertension (PAH). PDE5 is a cGMP-specific phosphodiesterase 
encoded by a single gene. Recent data show that PDE5 may modulate pressure-induced cardiac 
hypertrophy and fibrosis [34]. Although sildenafil has an acceptable degree of selectivity, 
increased specificity for PDE5, particularly over PDE1 and PDE6 will reduce or eliminate the 
incidence of visual disturbances associated with the flushing and headaches that are observed 
with sildenafil [84]. In the case of all the other PDE5 inhibitors that have been described in the 
peer-reviewed literature, improvements in selectivity were determined empirically, and 
compounds were optimized on the basis of structure- activity explorations of the chemical 
series in question. PDE5 is abundantly expressed in lung tissue and appears to be up regulated 
in PAH [85,86]. PDE5 is involved in endothelial dysfunction by inactivating cGMP, the second 
messenger of the nitric oxide (NO) pathway in the pulmonary vasculature [85-87]. It has been 
reported that sildenafil and vardenafil raise hippocampal cGMP levels and improve memory in 
aged rats [88] and mice [89]. 
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The PDE7 family is composed of two genes coding for high-affinity, rolipram-insensitive, 
cAMP-specific enzymes. The presence of high concentrations of PDE7 mRNA in the human 
striatum and dentate gyrus suggests that selective inhibitors could be used to increase 
cAMP concentration in these areas without some of the side effects associated with PDE4 
inhibition [40,90,91]. Several distinct PDE7 inhibitors have been reported [92,93]; however, 
their effects on central nervous system (CNS) function have yet to be described. It has been 
shown that selective inhibition of PDE7 or dual PDE4/7 inhibition may provide a novel 
therapeutic approach for the treatment of chronic lymphocytic leukemia (CLL) by 
enhancing killing and increasing specificity for CLL cells [94]. 
The company Pfizer reported on a small molecule called PF-04957325 that selectively 
inhibits PDE8 with an in vitro IC50 of 0.7nM against PDE8A, of 0.2nM against PDE8B, and 
>1.5μM against all other PDE isoforms [95]. PDE8-selective inhibitors might be used to 
correct adrenal insufficiency, and a PDE8 activator might be used to treat Cushing’s 
syndrome [96]. 
4. Pharmacological potential of PDE inhibitors for the treatment of cystic 
fibrosis  
As an important second messenger signaling molecule, cAMP controls a wide variety of 
eukaryotic and prokaryotic responses to extracellular cues [97]. For cAMP-dependent 
signaling pathways to be effective, the intracellular cAMP concentration is tightly controlled 
at the level of both of synthesis and degradation. CF is characterized by defective cAMP-
dependent chloride conductance in epithelial cells and is caused by a defect in the targeting 
of the chloride channel CFTR.  
4.1 Non selective PDE inhibitors 
Non specific inhibitors of the PDE such as IBMX, theophylline and DPMX (7-methyl-1,3 
dipropyl xanthine) have been shown to activate normal and mutated CFTR chloride 
channels in epithelia [98]. It is well known that the methylxanthines, found naturally in 
tea, coffee and cocoa, stimulate the central nervous system, relax bronchial smooth 
muscle, and stimulate cardiac muscle. These purine derivatives function as adenosine 
receptor antagonists and as PDE inhibitors. Due to impact on the cAMP pathway and 
activity at low concentrations, studies have been done looking at their effect on the cAMP 
activated CFTR channel. The PDE inhibitor, IBMX also functions as an adenosine receptor 
antagonist. It has been reported that IBMX increases the CFTR chloride current in 
Xenopus oocytes expressing the F508del-CFTR [99]. In 1993, when studying CF nasal 
bronchial epithelial tissues with F508del-CFTR, Grubb et al. found that IBMX (5 mM) 
associated to forskolin (0.01 mM) did not stimulate chloride efflux in vitro [100].  Haws et 
al. studied the effect of IBMX and 8-cyclopentyl-1,3-dipropylxanthine (CPX), another non 
specific PDE and an A1 adenosine receptor antagonist, on stably transfected cells with 
F508del-CFTR  [101]. In this study, both IBMX (5 mM) and CPX potentiated the effect of 
forskolin on CFTR-mediated efflux of 125I  by 2.5-fold. There was a 7-fold increase in 
cAMP levels associated with IBMX treatment, but not CPX treatment. A potentiation by 
IBMX of prostaglandin E (PGE2)-induced HCO3- secretion has been reported in the rat 
duodenum in vivo [102,103]. 
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4.2 Selective PDE inhibitors 
PDE inhibitors increase cAMP by inhibiting one or more enzymes involved in cAMP 
degradation. Cyclic AMP-activated PKA mediates phosphorylation of CFTR and increases the 
open probability of the CFTR channel. Drugs in this class include amrinone and milrinone. 
These drugs also cause vasodilation, which may be beneficial for the CF airways. In 1991, 
Drumm et al. showed that inhibiting PDE had a larger effect on CFTR activation than have 
adenylate cyclase stimulants [99]. Using airway epithelial cell lines expressing wild-type CFTR, 
Calu-3 and 16HBE cells, it has been found that, at 100µM concentrations, PDE 3 inhibitors 
(milrinone, amrinone) without adenylate cyclase activators, stimulate   chloride efflux 13.7-fold 
[104]. They found no effect on chloride efflux by IBMX, a non specific PDE, by rolipram, a PDE4 
inhibitor or by dipyridamole, a PDE5 inhibitor. The increase of channel efflux by the type 3 PDE 
inhibitor was not associated with a significant rise in cAMP concentrations but it was inhibited 
by protein kinase A inhibitors (H-8 and Rp-cAMPS), suggesting that it might work through a 
more distal signal. Kelley et al. also looked at endogenous CFTR in transformed nasal polyp 
tissue of patients homozygous for F508del (CF-T43) [105]. They found that, when administered 
in the presence of a ǃ-agonist (isoproterenol) and protein kinase A activator, milrinone and 
amrinone, at 100µM concentrations, increased chloride efflux by 19-61% from baseline. Mice 
homozygous for F508del Cftr were administered with a combination of milrinone (100 µM) and 
forskolin (10 µM) [106]. This combination of drugs resulted in an increased magnitude of the 
murine nasal potential difference (PD). The implications of this study are exciting; but the effect 
has not been confirmed by others [107]. 
It has been shown that CFTR has a major role in the regulation of duodenal HCO3- secretion 
[108]. Furthermore, O’Grady et al. [109] showed that both PDE1 and PDE3 are involved in the 
activation of CFTR in T84 cells and human colonic epithelial cells. In 2007, Hayashi M et al. 
[110] suggested that PDE1 and PDE3 are involved in the regulation of duodenal HCO3- 
secretion and that the response to PGE2 is associated with both PDE1 and PDE3, while the 
response to NO is mainly modulated by PDE1 [110]. McPherson et al. showed that a selective 
cyclic nucleotide PDE5 inhibitor partially corrected defective L-adrenergic stimulation of 
mucin secretion in CFTR antibody-inhibited submandibular cells. The PDE5 inhibitor did not 
increase cAMP levels, nor did it potentiate isoproterenol-induced cAMP rise [111]. Of note, 
Dormer et al. (2005) demonstrated that the PDE5 inhibitor sildenafil (Viagra) also acts as a 
pharmacological chaperone. Because sildenafil is approved for clinical use, they speculated 
that their data might speed up the development of new therapies for CF [7]. 
5. The clinical pharmacokinetics of PDE5 inhibitors 
Lung tissue is a rich source of PDE, including PDE5, the major function of which is 
acceleration of the decay of cGMP [112].  
5.1 Sildenafil 
Sildenafil citrate was the first selective PDE5 inhibitor approved for the treatment of erectile 
dysfunction. Sildenafil, however, is only approximately 10-fold as potent for PDE5 as for 
PDE6, which is found in the photoreceptors of the human retina. This lower selectivity 
toward PDE6 is presumed to be the cause for color vision abnormalities observed with high 
doses or plasma levels of sildenafil. 
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Sildenafil is relatively lipophilic with a weakly basic center in the piperazine tertiary amine, 
resulting in only partial ionization at physiological pH. Following oral administration, 
sildenafil is rapidly absorbed, reaching peak plasma concentrations within 1 hour (range, 
0.5-2 hours). The first-order absorption rate constant was estimated as 2.6 hours-1 based on 
population pharmacokinetic data in patients with erectile dysfunction [113]. Administration 
of sildenafil after a high-fat meal caused reductions in the rate of absorption and extent of 
systemic exposure. The time-to-peak (tmax) was delayed by approximately 1 hour, and 
maximum concentration (Cmax) was reduced by 29%. The systemic exposure of sildenafil 
after a high-fat meal was reduced by 11% [114]. 
Sildenafil is highly bound to plasma proteins, and the protein binding is independent of 
drug concentrations. After intravenous administration, the mean steady-state volume of 
distribution of sildenafil is 105 L, which substantially exceeds the total volume of body 
water (approximately 42 L), indicating distribution into tissues and possibly binding to 
extravascular proteins. Sildenafil is extensively metabolized, without unchanged sildenafil 
being detected in either urine or feces. After an oral dose, metabolites are predominantly 
excreted into the feces (73%-88%) and to a lesser extent into the urine (6%-15%) [115]. 
Plasma concentrations of sildenafil was reported to decline biexponentially, with a mean 
terminal half-life of 3 to 5 hours, independent of the route of administration [114]. Sildenafil 
is primarily metabolized by the cytochrome P-450 (CYP) isoenzyme CYP3A4 and to a lesser 
extent CYP2C9 [116]. Sildenafil is extensively metabolized, with more than 12 metabolites 
identified.  
The principal routes of metabolism are N-demethylation, oxidation, and aliphatic 
hydroxylation [115]. Plasma concentrations of N-demethylation are approximately 40% that of 
sildenafil, so that the metabolite accounts for approximately 20% of the pharmacological 
effects of sildenafil. The metabolite profile is qualitatively similar after intravenous and oral 
administration, but higher concentrations of N-desmethyl sildenafil after oral administration 
indicate the important role of first-pass metabolism in the metabolite formation. 
5.2 Vardenafil 
Vardenafil hydrochloride was the first second generation PDE5 inhibitor approved for the 
treatment of erectile dysfunction. Vardenafil has a high selectivity for the inhibition of PDE5 
compared with the other known phosphodiesterases [117,118]. Unlike sildenafil and 
tadalafil, vardenafil was developed from the outset specifically to treat erectile dysfunction.  
Vardenafil is rapidly absorbed, with plasma concentrations being detected in all subjects 
within 8 to 15 minutes after oral administration. 
Peak plasma concentrations were observed 0.25 to 3 hours after administration, with a 
median of 0.7 hours for the 20 and 40 mg dose level, and slightly later, with 0.9 hours for the 
10 mg dose level [117,119]. The absolute bioavailability of vardenafil was described as 
approximately 15%.  Vardenafil pharmacokinetics is largely unaffected by food containing 
moderate amounts of fat. Minimal changes (<15%) in mean vardenafil Cmax and no change 
in median tmax were observed when vardenafil was administered with a moderate-fat 
evening meal compared to dosing on an empty stomach. When 20mg oral vardenafil was 
administered immediately after consumption of a high-fat breakfast, the mean Cmax was 18% 
lower and the median tmax was delayed by 1 hour.  
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Based on in vitro investigations in human plasma, approximately 93% to 95% of the drug is 
bound to plasma proteins, approximately 80% to albumin, and 11% to ǂ1-acid glycoprotein 
[120]. It was also demonstrated that the binding to plasma proteins was fully reversible in 
all the tested species and was concentration independent. The major metabolite of 
vardenafil has similar protein-binding properties as the parent drug, with a bound fraction 
of 93% to 95%. The volume of distribution estimate for vardenafil after intravenous 
administration is relatively high, 208 L, implying extensive drug distribution into tissues. 
Vardenafil is extensively metabolized, with more than 14 metabolites identified. The major 
metabolite, M1, and 2 minor metabolites, M4 and M5, as well as their respective 
glucuronides, are all a result of the degradation of vardenafil’s piperazine ring. M1 is N-
desethyl vardenafil, M4 is reduced by a 2-carbon fragment of the piperazine ring of 
vardenafil, and M5 is the N-desethyl derivative of M4. Metabolism is predominantly 
mediated by CYP3A4 and to a smaller extent by CYP3A5 and CYP2C isoforms. All 3 
metabolites have pharmacologic activity. The major circulating metabolite, M1, has 28% of 
vardenafil’s potency for PDE5 inhibition, while M4 and M5 possess 5.6% and 4.9%, 
respectively [120].  
5.3 Tadalafil 
Tadalafil is a selective and potent inhibitor of PDE5 with an IC50 of 0.94 nM. It exhibits high 
selectivity toward PDE5 compared to other PDEs. Tadalafil is structurally different from 
both sildenafil and vardenafil, and the different structures are reflected in distinct 
differences in the clinical pharmacology profiles of these drugs [121]. Like sildenafil, 
tadalafil was developed initially for use in cardiovascular disease and was subsequently 
used for the treatment of erectile dysfunction [122]. Tadalafil was the last of the 3 PDE5 
inhibitors approved for erectile dysfunction.  
Tadalafil is rapidly absorbed after oral administration with a median time to reach peak 
plasma concentration of 2 hours (range, 0.5-6 hours) [118,121]. Absolute bioavailability of 
tadalafil following oral dosing has not been reported, but at least 36% of the dose is 
absorbed from an oral solution. The time course of oral absorption could successfully be 
modeled by a rapid first-order process. Population estimates of the first-order absorption 
rate constant from phase II and phase III studies are 1.75 and 1.86 hours–1, respectively [123]. 
The absorption and pharmacodynamic properties of tadalafil are not affected by either food 
or alcohol, and thus the drug can be administered without regard for food or alcohol 
consumption [124]. Smoking and body mass index had a weak effect on the 
pharmacokinetics of tadalafil. It has been reported that the clinical response to tadalafil may 
be evident as early as 16 minutes and may persist for up to 24 to 36 hours post dose 
[124,125]  
Tadalafil has an apparent volume of distribution of 60 to 70 L, with an interindividual 
variability of 40% to 50%. This indicates that tadalafil is distributed into tissues. Plasma 
protein binding was reported as 94%, with ǂ1-acid glycoprotein and albumin as principal 
binding proteins. A population pharmacokinetic analysis in patients taking tadalafil 
suggests a body weight dependency of the volume of distribution at steady state. 
Tadalafil is excreted primarily as inactive metabolites, mainly in the feces and to a lesser 
extent in urine. The mean elimination half-life for tadalafil was 17.5 hours, and the mean 
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apparent oral clearance was 2.5 L/h in healthy subjects [126]. The nearly exclusive 
elimination via hepatic metabolism and the relatively low value for oral clearance indicate 
that tadalafil has a low intrinsic clearance with regard to hepatic metabolism and can be 
classified as a drug with low hepatic extraction ratio. 
Tadalafil is primarily metabolized by CYP3A4 to a catechol metabolite, which further 
undergoes extensive methylation and glucuronidation to form methylcatechol and 
methylcatechol glucuronide metabolites.  This was confirmed by interaction studies with 
rifampin as potent CYP3A inducer and 
ketoconazole as a potent CYP3A inhibitor. The main circulating metabolite in plasma is 
methylcatechol glucuronide, which has a ≥ 10 000-fold less affinity for PDE5 than the 
analogue drug, tadalafil, and is thus expected to be clinically inactive at observed metabolite 
concentrations [126]. Several other inactive metabolites have also been identified in plasma, 
urine, or feces. 
5.4 Comparison of PDE5 inhibitors 
Although the 3 currently available PDE5 inhibitors, sildenafil, vardenafil, and tadalafil, have 
all shown to be effective in the treatment of erectile dysfunction, there are distinct 
differences between the compounds regarding their selectivity and specificity for PDE 
inhibition with consequences especially for the safety profile but also biopharmaceutic and 
pharmacokinetic disparities that largely affect the efficacy profile of these compounds. 
Sildenafil and vardenafil are very similar in terms of their chemical structure, whereas 
tadalafil with a methyldione structure differs markedly from sildenafil and vardenafil 
(Figure 2). These chemical similarities and differences are also reflected in similarities and 
dissimilarities of their clinical pharmacokinetics.  
All 3 PDE5 inhibitors are rapidly absorbed after oral administration, with peak 
concentrations reached slightly earlier for vardenafil compared to sildenafil and tadalafil. 
Although no clear concentration-effect relationships have been established for any of the 3 
PDE5 inhibitors, rapid absorption is considered an essential for a rapid onset of efficacy. 
Administration of a high-fat meal had no significant effect on the rate and extent of 
absorption of tadalafil but decreased the rate of absorption for sildenafil and vardenafil. All 
3 drugs are lipophilic and have a volume of distribution larger than the volume of total 
body water, indicating tissue uptake and binding. Furthermore, all 3 compounds are highly 
protein bound, with free plasma concentration fractions of only 4% to 6%.  
The major route of elimination for all PDE5 inhibitors is hepatic metabolism, with renal 
excretion of unchanged drug accounting for 1% or less of the elimination pathways. Based 
on their relatively high systemic clearance after intravenous administration, sildenafil and 
vardenafil can be classified as non restrictively cleared drugs with intermediate to high 
hepatic extraction ratio. The relatively comparable distribution volumes together with the 
substantial differences in systemic clearance among the PDE5 inhibitors result in distinct 
differences of the elimination half-life, 3 to 5 hours for sildenafil and vardenafil compared to 
17.5 hours for tadalafil. Tadalafil, however, has been detected in plasma even 5 days after 
oral administration due to its long half-life. This suggests the possibility of accumulation if 
taken regularly and in short intervals, which may result in an increased risk of side effects 
with the excessive use of this PDE5 inhibitor. 
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Fig. 2. Structures of selected examples of phosphodiesterase inhibitors. The figure shows 
various selective phosphodiesterase (PDE) inhibitors mentioned in this chapter. Of these, 
the PDE5 inhibitors sildenafil, vardenafil and tadalafil have been approved for treatment of 
erectile dysfunction. Sildenafil and vardenafil have also recently been approved as a 
treatment for pulmonary hypertension. 
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6. Administration of PDE5 inhibitors at clinical doses activates defective 
chloride transport in CF  
At present, many efforts are focused on CFTR pharmacotherapy which corrects the 
abnormal protein pharmacologically by various approaches such as the direct correction of 
stop codon mutations, CFTR channel activation, or correction of CFTR trafficking defects. 
High-throughput screening (HTS) has been used to identify molecules that increase F508del-
CFTR activity [127,129]. Such molecules have been categorized according to whether they 
alleviate the folding/cellular processing defect (correctors) or increase the responsiveness of 
F508del-CFTR channels already present in the membrane to cAMP activation (potentiators). 
Sildenafil has also been shown to correct F508del-CFTR processing when used at high 
micromolar concentrations [7].  
To test the hypothesis that PDE5 inhibitors (sildenafil, vardenafil and taladafil)  are able to 
restore transepithelial ion transport abnormalities of the F508del-CFTR protein, we have 
conducted experimental studies [9,10] in CF mice homozygous for the F508del mutation 
[130] and in their corresponding wild-type homozygous normal mice. The F508del-Cftr 
mouse model has been chosen because F508del is the most common and one of the most 
severe CF mutation and because the mouse model recapitulates, at different levels, the 
human disease. Epithelia of the F508del-CF mouse model are characterized by defective 
electrolyte transport, and Pseudomonas aeruginosa lipopolysaccharide (LPS) exposure mimics 
several aspects of CF airway epithelial inflammation such as increased pro-inflammatory 
cytokines, most notably interleukin (IL)-8, IL-6, and Tumor Necrosis Factor (TNF)-ǂ, and 
neutrophil infiltrate cells.  
In our protocols, CFTR function has been assessed in vivo by measuring the transepithelial 
nasal PD, a delicate technique that has been increasingly used as an index of therapeutic 
efficacy in novel fundamental therapies, either in animal models [9,10,131] or in CF 
patients [132]. Our results provide clear evidence that intraperitoneal injection of PDE5 
inhibitors (Figure 3), at clinical doses, to F508del-CF mice interact with CFTR, propping 
open the mutant protein to allow a normal flow of chloride ions across the epithelium of 
nasal mucosa, thereby completely restoring the decreased or even abolished CFTR-
dependent chloride transport [9]. In F508del mice, but not in Cftr knockout mice, the 
chloride conductance, evaluated by perfusing the nasal mucosa with a chloride-free 
solution in the presence of amiloride and with forskolin, is corrected 1 h after sildenafil 
administration. A more prolonged effect, persisting for at least 24 h, is observed with 
vardenafil. Moreover, vardenafil, but not sildenafil, is able to stimulate chloride transport 
associated with normal wild-type Cftr protein [9]. The forskolin response is increased 
after treatment with sildenafil or vardenafil in wild-type and in F508del mutant animals. 
In F508del mice, the chloride conductance in the presence of 200 µM DIDS (4-4’-
diisothiocyanostilbene-2,2’-disulphonic acid), an inhibitor of alternative chloride 
channels, was much higher after sildenafil injection than following placebo treatment 
(Figure 4). No effect on the sodium conductance was detected in any group of animals. 
Altogether, these data provide preclinical evidence that sildenafil and vardenafil 
stimulate, by a direct and not a by-pass effect, chloride transport activity of F508del-CFTR 
protein. 
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Fig. 3. Influence of vardenafil (24h after a single therapeutic dose) on ion transport evaluated 
by the nasal potential difference (PD) in F508del-CF mice. Chloride conductance in response 
to perfusion of the nasal mucosa with a solution without chloride and to forskolin is 
dramatically increased as compared to placebo-treated CF mice.  
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Fig. 4. Influence of sildenafil on Cftr -dependent chloride conductance evaluated by the 
nasal potential difference (PD) in the presence or the absence of DIDS, an inhibitor of 
alternative chloride conductance. Increased DIDS-insensitive conductance after sildenafil 
treatment reflects activation of Cftr function.  
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More recently, using a nebulizer setup specifically developed for mice (Figure 5), we have 
demonstrated that administration of PDE5 inhibitors through a single inhalation exposure is 
able to locally activate Cftr protein and correct the basic defects in CF [10] and that the effect 
lasts for at least 8 h (Figure 6). Our data have identified the inhalational route as a potential 
therapy for PDE5 inhibitors in CF. Consistent with our results, it has recently been 
demonstrated that the inhalation route of administration for vardenafil is associated with an 
acceptable safety profile. Apart from brief coughing on inspiration, no clinically significant 
changes in blood pressure or heart rate and no serious adverse events were recorded [133]. 
Inhalation drug therapy has several potential advantages over oral and intravenous routes, 
including rapid onset of pharmacological action, minimized systemic adverse effects and 
reduced effective drug doses compared to the same drug delivered orally [134]; this greatly 
highlights the impact of our work for translational science. 
 
 
 
 
 
 
 
A
B C
D
 
 
 
 
 
 
 
Fig. 5. Schematic representation of the whole-body immersion inhalation chamber setup we 
developed for a single mouse. (A) compressor, (B) nebulizer, (C) inhalation chamber with 
(D) expiratory gate. 
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Fig. 6. Duration of the correcting effect of inhaled vardenafil on chloride conductance, 
evaluated by nasal potential difference (PD) in F508del-CF mice 1, 4, 6, 8 and 24h after a 
single nebulisation with placebo or with vardenafil. The correcting effect of vardenafil lasts 
at least 8 h after inhalation.  
7. Intraperitoneal administration of PDE5 inhibitors administration at clinical 
doses attenuates exaggerated inflammatory responses in CF in vivo 
conditions 
Another important goal of mutation-specific CF treatment is attenuation of exaggerated 
lung inflammatory responses [134-137]. As lung inflammation plays a major role in morbi-
mortality in CF, identifying a therapeutic strategy that combines ability to correct the basic 
ion transport defect and to reduce dysregulated inflammatory responses is very exciting and 
promising. It has been reported that sildenafil reduces neutrophil lung infiltration in murine 
airways infected with P. aeruginosa [138]. In addition, toxicological studies have shown that 
sildenafil pretreatment attenuates acrolein-triggered airway inflammation associated with 
mucin overproduction [139]. 
More recently, we have found that vardenafil, selected as a representative PDE5 inhibitor 
for its longer-lasting Cftr activating effect, modulates the vicious circle of lung inflammation 
and attenuates the expression of pro-inflammatory cytokines and chemokines and cell 
infiltrates in the bronchoalveolar lavage (BAL) of CF and wild-type mice [140]  Our data 
indicate that intraperitoneal administration of a single pharmacological dose (0.14 mg/kg 
body weight) of vardenafil is followed by a reducing response in cell infiltrate and in the 
biosynthesis of several biomarkers of the inflammatory response. Most notably, levels of 
CCL-2 (chemokine C-C motif ligand), a cytokine playing a key role in the contribution of 
macrophages in the inflammatory response [136], are significantly reduced in the BAL fluid 
after vardenafil treatment, particularly in CF animals (Figure 7).  
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Fig. 7. Anti-inflammatory effect of in vivo treatment, by intraperitoneal injection, of a single 
therapeutic dose of vardenafil (vard) to F508del-CF (A) and wild-type (B) mice on the 
lipopolyssaccharide (LPS of P. aeruginosa) induced inflammatory response. Biosynthesis of 
CCL-2 is significantly reduced in the bronchoalveolar lavage (BAL) of vardenafil-treated  CF 
and non-CF animals. 
The mechanism of action of vardenafil as an anti-inflammatory agent in CF as well as the 
target-effector cells involved in these responses are under investigation by our group. 
Altogether, our data indicate that PDE5 inhibitors have a strong therapeutic potential for 
treating CF. A clinical trial aimed at investigating the safety and efficacy of sildenafil in CF 
lung disease is listed on www.clinicaltrials.gov (NCT00659529). 
8. Conclusions 
There is still no cure for CF. The CF patient may benefit from today’s privileged strategy 
which consists on targeting a pharmacological mutation-specific treatment. Currently 
candidate molecules suitable for CFTR pharmacotherapy are either being sought after or 
under investigation. Based on the high prevalence of F508del-CFTR mutation – more than 
two-thirds of patients with CF carry at least one copy of the allele -, strategies to rescue 
the functional status of the mutated protein will benefit most of the CF population. As 
PDE5 inhibitors such as sildenafil, vardenafil and tadalafil are able to correct 
transepithelial ion transport abnormalities and to limit exaggerated inflammatory 
responses related to the presence of F508del-CF protein, the drugs are promising 
compounds for fundamental pharmacotherapy in CF. Since the drugs are in clinical use, 
therapeutic approaches to address F508del-CFTR defects by PDE5 inhibitors could be 
considered as a ‘low-hanging fruit’ strategy in the drug discovery tree. The fact that such 
compounds have been approved for other therapeutic indications could speed up their 
development as CF therapeutics, as compared to other agents that are under investigation 
only for CF therapy and for which further exploratory studies are needed before being 
streamed towards clinical testing.  
In summary, CFTR correction with PDE5 inhibitors is a promising therapeutic approach 
based on functional correction of F508del-CFTR activity and on a possible anti-inflammatory 
action in F508del mice. The effects of these compounds on other CF mutation classes remain 
to be assessed.  
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